|
AU2003271274A1
|
|
Compositions and methods for increasing bone mineralization
|
|
AU2031102A
|
|
Selective MMP inhibitors having reduced side-effects
|
|
AU1014202A
|
|
Dosage forms comprising separate portions of R- and S-enantiomers
|
|
WO02053544A1
|
|
Pharmaceutical uses and synthesis of nicotinanilide-n-oxides
|
|
US6566384B1
|
|
Hydroxamic and carboxylic acid derivatives having MMP and TNF inhibitory activity
|
|
EP1286994A1
|
|
Hydroxamic and carboxylic acid derivatives having mmp and tnf inhibitory activity
|
|
AU5499401A
|
|
Hydroxamic and carboxylic acid derivatives having mmp and tnf inhibitory activity
|
|
WO0187870A1
|
|
Hydroxamic acid derivatives
|
|
GB0110770D0
|
|
Hydroxamic acid derivatives
|
|
GB0109554D0
|
|
Hydroxamic acid derivatives
|
|
GB0109557D0
|
|
Hydroxamic acid derivatives
|
|
GB0109553D0
|
|
Hydroxamic acid derivatives
|
|
GB0109551D0
|
|
Hydroxamic acid derivatives
|
|
GB0107361D0
|
|
Hydroxamic acid derivatives
|
|
GB0107359D0
|
|
Hydroxamic and carboxylic acid derivatives
|
|
GB0107362D0
|
|
Hydroxamic and carboxylic acid derivatives
|
|
GB0103892D0
|
|
Use
|
|
GB0103899D0
|
|
Use
|
|
GB0103894D0
|
|
Process
|
|
US6680338B2
|
|
Hydroxamic and carboxylic acid derivatives
|
